Bibliografía

1.- Anonymous.The search for blood substitutes. Scientific American. 1998; 73-77.

2.- Linares J. Transfusión de plasma y derivados. Inmunohematología y Transfusión. 1986; 349-385.

3.- Technical Manual. Blood Transfusion Practice. American Association of Blood Banks. 1996; 413-436.

4.-Wintrobe's Maxwell. Transfusion of blood and blood components. Clinical Hematology. 1993; 672-700.

5.-Manual de Hemostasia y Trombosis. Grupo CLAHT. Utilización de la sangre y sus componentes en los trastornos hemorrágicos.1990; 71-80.

6.-Smith Thier. Fisiopatología. El Hígado. 1987; 707, 1033.

7.-AHFS Drugs Information 2000. American Society of Health. System Pharmacist. Año 2000; 1298-1302, 2970-2980.

8.-Ruiz Reyes G. Proteínas Plasmáticas y sistema del complemento. Enciclopedia Iberoamericana. Universidad de Salamanca. 1992; 483-493.

9.-Ruiz Arguelles GJ. Terapéutica Transfusional. Fundamentos de Hematología. 1995;240-252.

10.-Martindale. The Extra Pharmacopoeia for Royal Pharmaceutical Society. 1996; 754-755.

11.-Editorial. Albumin-does the bell toll for thee?. Transfusion. 1999;39: 120-122.

12.-NHI Consensus Conference. Intravenous Immunoglobulin. Prevention and Treatment of disease. JAMA. 1990; 264: 3189-3193.

13.-Abd-Allah SA, Jansen PW, Ashwal S, et al. Intravenous immunoglobulin as therapy for Guillain-Barré syndrome. J. Child Neurol. 1997; 12: 376-380.

14.-Anon. Plasma exchange/Sandoglobulin ® Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997; 349: 225-230.

15.-Anon. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolona: a pilot study. Ann Neurol. 1994 a; 35: 749-752.

16.-Knapp MJ and Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharmacokinet. 1990; 9: 509-529.

17.-Jordan SC and Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol. 1994; 97(suppl 1): 31-38.

18.-Thornton CA and Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol. 1994; 35: 260-268.

19.-Dinarello CA. Is there a role for Interleukin-1 blockade in intravenous immunoglobulin therapy?. Immunol Rev. 1994; 139:173-188.

20.-CDC. Immune globulins for protection againts viral hepatitis. MMWR. 1981; 30: 423-434.

21.-Anon. Immune globulins for protection againts viral hepatitis. Ann Intern Med. 1982; 96: 193-197.

22.-Winokur PL and Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis. 1992; 14:580-586.

23.-CDC. Adult immunization: Recommendations of the Immunizations Practice Advisory Committee. MMWR. 1984 a; 33:1.

24.-Product Information: Gammastan®, immune globulin intravenous. Cutter Laboratories, Emeryville, CA. 1986.

25.-Product Information: Gammar®-IM, immune globulin intramuscular. Armour Pharmaceutical Company, Blue Bell, PA. 1995.

26.-Sullivan KM et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990; 323: 705-12.

27.-Winston DJ et al. Intravenous immune globulin for prevention of citomegalovirus infection and intersticial pneumonia after bone marrow transplantation. Ann Intern Med. 1987; 106: 12-18.

28.-Emanuel D et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988; 109:777-82.

29.-Wolff SN et al. High-dose weekly intravenous immuneglobulin to prevent infections in patients undergoing autologous bone marrow transplantation on severe myelo suppressive therapy: a study of the American Bone Marrow Transplant Group. Ann Intern Med. 1993;118: 937-42.

30.-Newburger JW et al. A single intravenous infusion of gammaglobulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991; 324: 1633-9.

31.-Dajani AS et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87: 1776-80.

32.-Sundel RP et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993; 123: 657-9.

33.-Howard RS. Neurology. Br Med J. 1994; 309: 392-5.

34.-Morris K, Rylance G. Guillain-Barré syndrome after measles, mumps and rubella vaccine. Lancet. 1994; 343: 60.

35.-Anonymous. Guillain-Barré syndrome: immunoglobulins or steroids?. WHO Drug Inf. 1993; 7:110-11.

36.-Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolona in Guillain-Barré syndrome. Lancet. 1993; 34: 586-90.

37.-Rees J. Guillain-Barré syndrome: the latest on treatment. Br J Hosp Med. 1993; 50: 226-9.

38.-The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985; 35: 1096-1104.

39.-French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficacy of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987; 22: 753-61.

40.-van der Maché FGA et al. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992; 326: 1123-9.

41.-Mc GheeB and Jarjour IT. Single dose intravenous immune globulin for treatment of Guillain-Barré syndrome. Am J Hosp Pharm. 1994; 51: 97-99.

42.-Urtasun M, Lopez de Munain A, Carrera N, et al. High-dose intravenous immune globulin in the management of severe Guillain-Barré syndrome. Ann Pharmacother. 1992; 26: 32-33.

43.-Pennington JE. Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob Agents Chemother. 1990; 34: 1463-6.

44.-National Institutes of Health Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA. 1990; 264: 3189-93.

45.-Anonymous. Consensus on IVIG. Lancet. 1990; 336: 470-2.

46.-ASHP Commission on Therapeutics. ASHP therapeutic guidelines for intravenous immune globulin. Clin Pharm. 1992; 11: 117-36.

47.-Anonymous. Results of the NICHD clinical trial of the efficacy of intravenous immunoglobulin for the prophylaxis of serious bacterial infections in symptomatic HIV-infected children. National Institute of Child Health and Human Development (NICHD). U.S. National Library of Medicine. 1991.

48.-Whitelaw A. Treatment of sepsis with IgG in very low birth-weight infants. Arch Dis Child. 1990; 65: 347-8.

49.-Noya FJD, Baker CJ. Intravenously administered immune globulin for premature infants: a time to wait. J Pediatr. 1989; 115: 969-71.

50.-Acunas BA et al. Effect of fresh frozen plasma and gammaglobulin on humoral immunity in neonatal sepsis. Arch Dis Child. 1994; 70F: 182-7.

51.-Carreras LO et al. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet. 1988; ii;393-4.

52.-Francois A et al. Repeated fetallosses and the lupus anticoagulant. Ann Intern Med. 1088; 109: 993-4.

53.-Parke A et al. Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med. 1989; 110: 495-6.

54.-Katz VL et al. Human immunoglobulin therapy for pre-eclampsia associated with lupus anticoagulant and cardiolipin antibody. Obstet Gynecol. 1990; 70: 986-8.

55.-Mueller-Eckhardt G et al. IVIG to prevent recurrent spontaneous abortion. Lancet. 1991; 337: 424-5.

56.-Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use intravenously administered immunoglobulin preparations. JAMA. 1995; 273:1865-1870.

57.-Arsura EL, Bick A, Brunner NG et al. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci. 1988; 295: 438-443.

58.-Gajdos PH. Intravenous immuneglobulin in myasthenia gravis. Clin Exp Immunol. 1994; 97 (suppl 1):49-51.

59.-Ferrero B, Durelli L, Cavallo R et al. Therapies for ezacerbation of myasthenia gravis: the machanism of action of intravenous high-dose immunoglobulin G. Ann N Y Acad Sci. 1993; 681: 563-566.

60.-Misbah SA and Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf. 1993;9: 254-262.